Liver Disease Diagnostics Market By Technique (imaging, laboratory tests, endoscopy, biopsy), By End Use (hospitals, laboratories, others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The liver disease diagnostics market was valued at $34,520.4 million in 2021 and is estimated to reach $61,962.1 million by 2031, growing at a CAGR of 6.1% from 2022 to 2031.
The liver is a vital organ of the body and has more than 500 functions and primary functions such as bile production & excretion, as excretion as bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins, and helps in blood purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to infection (parasites and viruses), chronic alcohol abuse, fat accumulation in the liver, immune system abnormality, and inheritance (hemochromatosis, hyperoxaluria, and Wilson’s disease)
Various techniques are used for the diagnosis of liver diseases such as imaging, laboratory tests, endoscopy, and biopsy. An increase in the use of imaging such as MRI, CT scan, and laboratory for the diagnosis of liver diseases boosts the growth of the liver disease diagnostics market.
Major factors that drive the growth of the liver disease diagnostics market include a rise in technological advancements, and an increase in the prevalence rate of chronic liver diseases such as hepatitis, chronic hepatitis B, chronic hepatitis C, and nonalcohol-related fatty liver disease (NAFLD). In addition, other liver diseases include infiltrative liver disorders (e.g., hepatic sarcoidosis and amyloidosis), alpha-1 antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis.
For instance, according to a report by the World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people had chronic hepatitis C virus infection, with around 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have chronic hepatitis C infection. Hence, such factors increase the demand for liver disease diagnostics.
However, unfavorable reimbursements, as well as complications such as the dearth of trained physicians & endoscopists, side effects of biopsy, and high costs associated with liver disease diagnostic products, are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for liver disease diagnostics manufacturers worldwide in the future.
Furthermore, the healthcare business is projected to witness growth, owing to a rise in the prevalence of chronic liver diseases, hepatitis, and liver cancer; an increase in R&D investments in drug discovery & development, and a rise in awareness regarding the minimally invasive diagnostic procedure for liver diseases. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.
The liver disease diagnostics market is segmented on the basis of technique, end user, and region. On the basis of technique, the market is classified into imaging, laboratory tests, endoscopy, and biopsy. Depending on the end user, it is fragmented into hospitals, laboratories, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major players profiled in the report are Abbott Laboratories, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd, Echosens, Fujifilm Holdings Corporation, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens AG, Thermo Fisher Scientific Inc., and Trivitron Healthcare.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the liver disease diagnostics market analysis from 2021 to 2031 to identify the prevailing liver disease diagnostics market opportunities.
Market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the liver disease diagnostics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global liver disease diagnostics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technique
endoscopy
biopsy
imaging
laboratory tests
By End Use
hospitals
laboratories
others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Abbott Laboratories
Bio-Rad Laboratories Inc.
Cosara Diagnostics Pvt Ltd
Echosens
Meril Life Sciences Pvt. Ltd.
PerkinElmer
Qiagen N.V.
Siemen’s AG
Thermo Fisher Scientific Inc.
Trivitron Healthcare
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 imaging
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 laboratory tests
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 endoscopy
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 biopsy
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- CHAPTER 5: LIVER DISEASE DIAGNOSTICS MARKET, BY END USE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 hospitals
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 laboratories
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: LIVER DISEASE DIAGNOSTICS MARKET, BY REGION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Technique
- 6.2.3 North America Market size and forecast, by End Use
- 6.2.4 North America Market size and forecast, by country
- 6.2.4.1 U.S.
- 6.2.4.1.1 Market size and forecast, by Technique
- 6.2.4.1.2 Market size and forecast, by End Use
- 6.2.4.2 Canada
- 6.2.4.2.1 Market size and forecast, by Technique
- 6.2.4.2.2 Market size and forecast, by End Use
- 6.2.4.3 Mexico
- 6.2.4.3.1 Market size and forecast, by Technique
- 6.2.4.3.2 Market size and forecast, by End Use
- 6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Technique
- 6.3.3 Europe Market size and forecast, by End Use
- 6.3.4 Europe Market size and forecast, by country
- 6.3.4.1 Germany
- 6.3.4.1.1 Market size and forecast, by Technique
- 6.3.4.1.2 Market size and forecast, by End Use
- 6.3.4.2 France
- 6.3.4.2.1 Market size and forecast, by Technique
- 6.3.4.2.2 Market size and forecast, by End Use
- 6.3.4.3 UK
- 6.3.4.3.1 Market size and forecast, by Technique
- 6.3.4.3.2 Market size and forecast, by End Use
- 6.3.4.4 Italy
- 6.3.4.4.1 Market size and forecast, by Technique
- 6.3.4.4.2 Market size and forecast, by End Use
- 6.3.4.5 Spain
- 6.3.4.5.1 Market size and forecast, by Technique
- 6.3.4.5.2 Market size and forecast, by End Use
- 6.3.4.6 Rest of Europe
- 6.3.4.6.1 Market size and forecast, by Technique
- 6.3.4.6.2 Market size and forecast, by End Use
- 6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Technique
- 6.4.3 Asia-Pacific Market size and forecast, by End Use
- 6.4.4 Asia-Pacific Market size and forecast, by country
- 6.4.4.1 China
- 6.4.4.1.1 Market size and forecast, by Technique
- 6.4.4.1.2 Market size and forecast, by End Use
- 6.4.4.2 Japan
- 6.4.4.2.1 Market size and forecast, by Technique
- 6.4.4.2.2 Market size and forecast, by End Use
- 6.4.4.3 India
- 6.4.4.3.1 Market size and forecast, by Technique
- 6.4.4.3.2 Market size and forecast, by End Use
- 6.4.4.4 South Korea
- 6.4.4.4.1 Market size and forecast, by Technique
- 6.4.4.4.2 Market size and forecast, by End Use
- 6.4.4.5 Australia
- 6.4.4.5.1 Market size and forecast, by Technique
- 6.4.4.5.2 Market size and forecast, by End Use
- 6.4.4.6 Rest of Asia-Pacific
- 6.4.4.6.1 Market size and forecast, by Technique
- 6.4.4.6.2 Market size and forecast, by End Use
- 6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Technique
- 6.5.3 LAMEA Market size and forecast, by End Use
- 6.5.4 LAMEA Market size and forecast, by country
- 6.5.4.1 Brazil
- 6.5.4.1.1 Market size and forecast, by Technique
- 6.5.4.1.2 Market size and forecast, by End Use
- 6.5.4.2 Saudi Arabia
- 6.5.4.2.1 Market size and forecast, by Technique
- 6.5.4.2.2 Market size and forecast, by End Use
- 6.5.4.3 South Africa
- 6.5.4.3.1 Market size and forecast, by Technique
- 6.5.4.3.2 Market size and forecast, by End Use
- 6.5.4.4 Rest of LAMEA
- 6.5.4.4.1 Market size and forecast, by Technique
- 6.5.4.4.2 Market size and forecast, by End Use
- CHAPTER 7: COMPANY LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Key developments
- CHAPTER 8: COMPANY PROFILES
- 8.1 Abbott Laboratories
- 8.1.1 Company overview
- 8.1.2 Company snapshot
- 8.1.3 Operating business segments
- 8.1.4 Product portfolio
- 8.1.5 Business performance
- 8.1.6 Key strategic moves and developments
- 8.2 Bio-Rad Laboratories Inc.
- 8.2.1 Company overview
- 8.2.2 Company snapshot
- 8.2.3 Operating business segments
- 8.2.4 Product portfolio
- 8.2.5 Business performance
- 8.2.6 Key strategic moves and developments
- 8.3 Cosara Diagnostics Pvt Ltd
- 8.3.1 Company overview
- 8.3.2 Company snapshot
- 8.3.3 Operating business segments
- 8.3.4 Product portfolio
- 8.3.5 Business performance
- 8.3.6 Key strategic moves and developments
- 8.4 Echosens
- 8.4.1 Company overview
- 8.4.2 Company snapshot
- 8.4.3 Operating business segments
- 8.4.4 Product portfolio
- 8.4.5 Business performance
- 8.4.6 Key strategic moves and developments
- 8.5 Meril Life Sciences Pvt. Ltd.
- 8.5.1 Company overview
- 8.5.2 Company snapshot
- 8.5.3 Operating business segments
- 8.5.4 Product portfolio
- 8.5.5 Business performance
- 8.5.6 Key strategic moves and developments
- 8.6 PerkinElmer
- 8.6.1 Company overview
- 8.6.2 Company snapshot
- 8.6.3 Operating business segments
- 8.6.4 Product portfolio
- 8.6.5 Business performance
- 8.6.6 Key strategic moves and developments
- 8.7 Qiagen N.V.
- 8.7.1 Company overview
- 8.7.2 Company snapshot
- 8.7.3 Operating business segments
- 8.7.4 Product portfolio
- 8.7.5 Business performance
- 8.7.6 Key strategic moves and developments
- 8.8 Siemen’s AG
- 8.8.1 Company overview
- 8.8.2 Company snapshot
- 8.8.3 Operating business segments
- 8.8.4 Product portfolio
- 8.8.5 Business performance
- 8.8.6 Key strategic moves and developments
- 8.9 Thermo Fisher Scientific Inc.
- 8.9.1 Company overview
- 8.9.2 Company snapshot
- 8.9.3 Operating business segments
- 8.9.4 Product portfolio
- 8.9.5 Business performance
- 8.9.6 Key strategic moves and developments
- 8.10 Trivitron Healthcare
- 8.10.1 Company overview
- 8.10.2 Company snapshot
- 8.10.3 Operating business segments
- 8.10.4 Product portfolio
- 8.10.5 Business performance
- 8.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 2. LIVER DISEASE DIAGNOSTICS MARKET, FOR IMAGING, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. LIVER DISEASE DIAGNOSTICS MARKET FOR IMAGING, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORY TESTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. LIVER DISEASE DIAGNOSTICS MARKET, FOR ENDOSCOPY, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. LIVER DISEASE DIAGNOSTICS MARKET FOR ENDOSCOPY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. LIVER DISEASE DIAGNOSTICS MARKET, FOR BIOPSY, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. LIVER DISEASE DIAGNOSTICS MARKET FOR BIOPSY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. GLOBAL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 11. LIVER DISEASE DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
- TABLE 12. LIVER DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 13. LIVER DISEASE DIAGNOSTICS MARKET, FOR LABORATORIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. LIVER DISEASE DIAGNOSTICS MARKET FOR LABORATORIES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. LIVER DISEASE DIAGNOSTICS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. LIVER DISEASE DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. LIVER DISEASE DIAGNOSTICS MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 19. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 20. NORTH AMERICA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 22. U.S. LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 23. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 24. CANADA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 25. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 26. MEXICO LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 27. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 28. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 29. EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 30. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 31. GERMANY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 32. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 33. FRANCE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 34. UK LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 35. UK LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 36. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 37. ITALY LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 38. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 39. SPAIN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 40. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 41. REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 42. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 43. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 44. ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 45. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 46. CHINA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 47. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 48. JAPAN LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 49. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 50. INDIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 51. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 52. SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 53. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 54. AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 55. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 56. REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 57. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 58. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 59. LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 60. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 61. BRAZIL LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 62. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 63. SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 64. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 65. SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 66. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 67. REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET, BY END USE, 2021-2031 ($MILLION)
- TABLE 68.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 69.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 70.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 71.ABBOTT LABORATORIES: NET SALES,
- TABLE 72.ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 73.BIO-RAD LABORATORIES INC.: COMPANY SNAPSHOT
- TABLE 74.BIO-RAD LABORATORIES INC.: OPERATING SEGMENTS
- TABLE 75.BIO-RAD LABORATORIES INC.: PRODUCT PORTFOLIO
- TABLE 76.BIO-RAD LABORATORIES INC.: NET SALES,
- TABLE 77.BIO-RAD LABORATORIES INC.: KEY STRATERGIES
- TABLE 78.COSARA DIAGNOSTICS PVT LTD: COMPANY SNAPSHOT
- TABLE 79.COSARA DIAGNOSTICS PVT LTD: OPERATING SEGMENTS
- TABLE 80.COSARA DIAGNOSTICS PVT LTD: PRODUCT PORTFOLIO
- TABLE 81.COSARA DIAGNOSTICS PVT LTD: NET SALES,
- TABLE 82.COSARA DIAGNOSTICS PVT LTD: KEY STRATERGIES
- TABLE 83.ECHOSENS: COMPANY SNAPSHOT
- TABLE 84.ECHOSENS: OPERATING SEGMENTS
- TABLE 85.ECHOSENS: PRODUCT PORTFOLIO
- TABLE 86.ECHOSENS: NET SALES,
- TABLE 87.ECHOSENS: KEY STRATERGIES
- TABLE 88.MERIL LIFE SCIENCES PVT. LTD.: COMPANY SNAPSHOT
- TABLE 89.MERIL LIFE SCIENCES PVT. LTD.: OPERATING SEGMENTS
- TABLE 90.MERIL LIFE SCIENCES PVT. LTD.: PRODUCT PORTFOLIO
- TABLE 91.MERIL LIFE SCIENCES PVT. LTD.: NET SALES,
- TABLE 92.MERIL LIFE SCIENCES PVT. LTD.: KEY STRATERGIES
- TABLE 93.PERKINELMER: COMPANY SNAPSHOT
- TABLE 94.PERKINELMER: OPERATING SEGMENTS
- TABLE 95.PERKINELMER: PRODUCT PORTFOLIO
- TABLE 96.PERKINELMER: NET SALES,
- TABLE 97.PERKINELMER: KEY STRATERGIES
- TABLE 98.QIAGEN N.V.: COMPANY SNAPSHOT
- TABLE 99.QIAGEN N.V.: OPERATING SEGMENTS
- TABLE 100.QIAGEN N.V.: PRODUCT PORTFOLIO
- TABLE 101.QIAGEN N.V.: NET SALES,
- TABLE 102.QIAGEN N.V.: KEY STRATERGIES
- TABLE 103.SIEMEN’S AG: COMPANY SNAPSHOT
- TABLE 104.SIEMEN’S AG: OPERATING SEGMENTS
- TABLE 105.SIEMEN’S AG: PRODUCT PORTFOLIO
- TABLE 106.SIEMEN’S AG: NET SALES,
- TABLE 107.SIEMEN’S AG: KEY STRATERGIES
- TABLE 108.THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- TABLE 109.THERMO FISHER SCIENTIFIC INC.: OPERATING SEGMENTS
- TABLE 110.THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
- TABLE 111.THERMO FISHER SCIENTIFIC INC.: NET SALES,
- TABLE 112.THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
- TABLE 113.TRIVITRON HEALTHCARE: COMPANY SNAPSHOT
- TABLE 114.TRIVITRON HEALTHCARE: OPERATING SEGMENTS
- TABLE 115.TRIVITRON HEALTHCARE: PRODUCT PORTFOLIO
- TABLE 116.TRIVITRON HEALTHCARE: NET SALES,
- TABLE 117.TRIVITRON HEALTHCARE: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.LIVER DISEASE DIAGNOSTICS MARKET SEGMENTATION
- FIGURE 2.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031
- FIGURE 3.LIVER DISEASE DIAGNOSTICS MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.LIVER DISEASE DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.LIVER DISEASE DIAGNOSTICS MARKET,BY TECHNIQUE,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF IMAGING LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF LABORATORY TESTS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BIOPSY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
- FIGURE 17.LIVER DISEASE DIAGNOSTICS MARKET,BY END USE,2021(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF LABORATORIES LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS LIVER DISEASE DIAGNOSTICS MARKET,2021-2031(%)
- FIGURE 21.LIVER DISEASE DIAGNOSTICS MARKET BY REGION,2021
- FIGURE 22.U.S. LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 23.CANADA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 24.MEXICO LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 25.GERMANY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 26.FRANCE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 27.UK LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 28.ITALY LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 29.SPAIN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 30.REST OF EUROPE LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 31.CHINA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 32.JAPAN LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 33.INDIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 34.SOUTH KOREA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 35.AUSTRALIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 36.REST OF ASIA-PACIFIC LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 37.BRAZIL LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 38.SAUDI ARABIA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 39.SOUTH AFRICA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 40.REST OF LAMEA LIVER DISEASE DIAGNOSTICS MARKET,2021-2031($MILLION)
- FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 45.COMPETITIVE DASHBOARD
- FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 47.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
- FIGURE 48.BIO-RAD LABORATORIES INC..: NET SALES ,($MILLION)
- FIGURE 49.COSARA DIAGNOSTICS PVT LTD.: NET SALES ,($MILLION)
- FIGURE 50.ECHOSENS.: NET SALES ,($MILLION)
- FIGURE 51.MERIL LIFE SCIENCES PVT. LTD..: NET SALES ,($MILLION)
- FIGURE 52.PERKINELMER.: NET SALES ,($MILLION)
- FIGURE 53.QIAGEN N.V..: NET SALES ,($MILLION)
- FIGURE 54.SIEMEN’S AG.: NET SALES ,($MILLION)
- FIGURE 55.THERMO FISHER SCIENTIFIC INC..: NET SALES ,($MILLION)
- FIGURE 56.TRIVITRON HEALTHCARE.: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook